3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Breast
1
Conditions
Colorectal Neoplasms
56
Ovarian Neoplasms
39
Carcinoma, Hepatocellular
39
Neoplasms
25
Fallopian Tube Neoplasms
21
Carcinoma, Non-Small-Cell Lung
20
Endometrial Neoplasms
15
Glioblastoma
11
Breast Neoplasms
11
Brain Neoplasms
11
Neoplasm Metastasis
10
Colonic Neoplasms
10
Lung Neoplasms
8
Liver Neoplasms
8
Uterine Cervical Neoplasms
7
Stomach Neoplasms
6
Rectal Neoplasms
6
Glioma
6
Biliary Tract Neoplasms
6
Carcinoma, Ovarian Epithelial
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Gastrointestinal Neoplasms
4
Digestive System Neoplasms
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Recurrence
3
Peritoneal Neoplasms
3
Pancreatic Neoplasms
3
Interventions
pembrolizumab
3
Paclitaxel
2
Carboplatin
2
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
selinexor
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
dostarlimab
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Vaginal Smears
1
VMBP protocol
1
Ultrasound, High-Intensity Focused, Transrectal
1
Trastuzumab
1
Sutures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
Bevacizumab
×
90 days
×
Clear all
NCT05579366
2026-06-03
RAINFOL-01
Genmab
Phase 1/2
Recruiting
884 enrolled